Diagnostic Applications of Nuclear Medicine: Malignant Melanoma
- Author(s)
- Scott, AM; Lee, ST; Senko, C; Ciprotti, M; Kee, D;
- Journal Title
- In: Volterrani, D., Erba, P.A., Strauss, H.W., Mariani, G., Larson, S.M. (eds) Nuclear Oncology: From Pathophysiology to Clinical Applications, Third Edition
- Publication Type
- Book section
- Abstract
- Malignant melanoma was diagnosed in approximately 74,000 patients in 2015 in the USA. Melanoma accounts for about 3% of all skin cancers. Major parameters that impact prognosis include Breslow thickness, ulceration, tumor location, growth pattern, histological subtype, patient’s age, gender, and tumor status of regional lymph nodes. Melanomas are staged using the American Joint Committee on Cancer (AJCC) TNM system, which has incorporated the histological status of SLN into its latest staging system version of cutaneous malignant melanoma.
- Publisher
- Springer International Publishing
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1007/978-3-031-05494-5_24
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-04-03 06:48:22
Last Modified: 2025-04-03 06:49:14